Q1 2018 13F Holders as of 31 Mar 2018
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Number of holders
-
21
-
Total 13F shares, excl. options
-
4,683,937
-
Shares change
-
+4,683,937
-
Total reported value, excl. options
-
$47,805,000
-
Value change
-
+$47,804,999
-
Number of buys
-
21
-
Price
-
$10.24
Significant Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q1 2018
21 filings reported holding BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2018.
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) has 21 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4,683,937 shares
of 6,235,531 outstanding shares and own 75.12% of the company stock.
Largest 10 shareholders include FMR LLC (1,666,666 shares), Artemis Investment Management LLP (1,210,435 shares), BARCLAYS PLC (618,249 shares), CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM (328,300 shares), VANGUARD GROUP INC (295,000 shares), ASCEND CAPITAL, LLC (200,497 shares), Monashee Investment Management LLC (90,000 shares), Marshall Wace North America L.P. (65,412 shares), Point72 Asset Management, L.P. (59,451 shares), and Dean Capital Investments Management, LLC (35,556 shares).
This table shows the top 21 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.